The BEACON trial evaluated the combination of encorafenib with cetuximab (an EGFR inhibitor), and in some cases, binimetinib (a MEK inhibitor), in patients with metastatic CRC with BRAF V600E mutation. The gene discussed is EGFR; the disease is colorectal carcinoma.